241127-58-2

Novel antitumor agent that induces apoptosis in tumor cells through inhibition of the tyrosine kinase BCR/ABL.

Adaphostin is a p210bcr/abl tyrosine kinase inhibitor and a potent inducer of myeloid cell death. 
Adaphostin is a p210bcr/abl tyrosine kinase inhibitor displaying anti-proliferative activity in leukemia models, human prostate cancer cell line PC-3 and other cancer cell lines. Adaphostin is a potent inducer of myeloid cell death. Similarly to AG957, adaphostin appears to induce a degradation of WT and mutated Bcr/Abl.

p210 bcr/abl tyrosine kinase inhibitor (IC 50 = 14 μ M). Induces apoptosis in T-lymphoblastic human leukemia cell lines (IC 50 values range from 16.8 to 216.3 nM) in vitro . Displays selectivity for chronic myelogenous leukemia (CML) myeloid progenitors in vitro .

[1] P A SVINGEN. Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro.[J]. Clinical Cancer Research, 2000, 6 1: 237-249.
[2] IOANNIS A AVRAMIS. In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines.[J]. Cancer Chemotherapy and Pharmacology, 2002, 50 6: 479-489. DOI:10.1007/s00280-002-0507-6.
[3] NADA ORSOLIC. Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells[J]. Cancer Science, 2006, 97 9: 952-960. DOI:10.1111/j.1349-7006.2006.00269.x.
[4] JOYA CHANDRA. Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells.[J]. Blood, 2003, 102 13: 4512-4519. DOI:10.1182/blood-2003-02-0562.
[5] KOUTAROH OKADA. Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.[J]. ACS Catalysis , 2019: 105-119. DOI:10.1016/j.ebiom.2019.01.019.